0 12 Constitutive constitutive JJ 13 23 activation activation NN 24 26 of of IN 27 36 NF-kappaB NF-kappaB NNP 37 39 in in IN 40 47 primary primary JJ 48 53 adult adult JJ 54 60 T-cell t-cell NN 61 69 leukemia leukemia NN 70 75 cells cell NNS 75 76 . . . 78 83 Human human JJ 84 90 T-cell T-cell NNP 91 99 leukemia leukemia NN 100 105 virus virus NN 106 110 type type NN 111 112 I i CD 113 114 ( ( ( 114 120 HTLV-I HTLV-I NNP 120 121 ) ) ) 122 124 is be VBZ 125 127 an an DT 128 137 etiologic etiologic JJ 138 143 agent agent NN 144 146 of of IN 147 152 adult adult JJ 153 159 T-cell t-cell NN 160 168 leukemia leukemia NN 169 170 ( ( ( 170 173 ATL ATL NNP 173 174 ) ) ) 174 175 . . . 176 179 The the DT 180 185 viral viral JJ 186 193 protein protein NN 194 197 Tax Tax NNP 198 205 induces induce VBZ 206 209 the the DT 210 220 activation activation NN 221 224 and and CC 225 232 nuclear nuclear JJ 233 250 translocalization translocalization NN 251 253 of of IN 254 267 transcription transcription NN 268 274 factor factor NN 275 284 NF-kappaB NF-kappaB NNP 284 285 , , , 286 291 which which WDT 292 294 is be VBZ 295 303 proposed propose VBN 304 306 to to TO 307 311 play play VB 312 313 a a DT 314 321 crucial crucial JJ 322 326 role role NN 327 329 in in IN 330 333 the the DT 334 348 transformation transformation NN 349 351 of of IN 352 353 T t NN 354 359 cells cell NNS 360 362 by by IN 363 369 HTLV-I HTLV-I NNP 369 370 . . . 371 378 However however RB 378 379 , , , 380 383 the the DT 384 390 HTLV-I HTLV-I NNP 391 396 genes gene NNS 397 406 including include VBG 407 410 Tax Tax NNP 411 414 are be VBP 415 418 not not RB 419 428 expressed express VBN 429 442 significantly significantly RB 443 445 in in IN 446 453 primary primary JJ 454 462 leukemic leukemic JJ 463 468 cells cell NNS 469 473 from from IN 474 477 ATL atl NN 478 486 patients patient NNS 486 487 . . . 488 490 In in IN 491 495 this this DT 496 501 study study NN 501 502 , , , 503 505 we we PRP 506 514 examined examine VBD 515 518 the the DT 519 524 basis basis NN 525 528 for for IN 529 538 NF-kappaB NF-kappaB NNP 539 549 activation activation NN 550 552 in in IN 553 560 freshly freshly RB 561 569 isolated isolate VBN 570 578 leukemic leukemic JJ 579 584 cells cell NNS 585 589 from from IN 590 593 ATL atl NN 594 602 patients patient NNS 602 603 . . . 604 606 We we PRP 607 612 found find VBD 613 617 that that IN 618 626 leukemic leukemic JJ 627 632 cells cell NNS 633 637 from from IN 638 641 ATL atl NN 642 650 patients patient NNS 650 651 , , , 652 656 like like IN 657 672 HTLV-I-infected htlv-i-infected JJ 673 679 T-cell t-cell NN 680 685 lines line NNS 685 686 , , , 687 694 display display VBP 695 707 constitutive constitutive JJ 708 717 NF-kappaB NF-kappaB NNP 718 721 DNA DNA NNP 722 729 binding binding NN 730 738 activity activity NN 739 742 and and CC 743 752 increased increase VBN 753 764 degradation degradation NN 765 767 of of IN 768 780 IkappaBalpha IkappaBalpha NNP 781 782 ( ( ( 782 784 an an DT 785 794 inhibitor inhibitor NN 795 797 of of IN 798 807 NF-kappaB NF-kappaB NNP 807 808 ) ) ) 808 809 . . . 810 817 Whereas whereas IN 818 821 the the DT 822 831 NF-kappaB NF-kappaB NNP 832 839 binding binding NN 840 848 activity activity NN 849 851 in in IN 852 866 Tax-expressing tax-expressing JJ 867 873 T-cell t-cell NN 874 879 lines line NNS 880 889 consisted consist VBD 890 896 mostly mostly RB 897 899 of of IN 900 909 p50/c-Rel p50/c-rel NN 909 910 , , , 911 916 fresh fresh JJ 917 920 ATL ATL NNP 921 928 samples sample NNS 929 938 contained contain VBD 939 946 p50/p50 p50/p50 NN 947 950 and and CC 951 958 p50/p65 p50/p65 NN 959 971 heterodimers heterodimer NNS 971 972 . . . 973 976 One one CD 977 983 T-cell t-cell NN 984 988 line line NN 989 996 derived derive VBN 997 1001 from from IN 1002 1005 ATL ATL NNP 1006 1014 leukemic leukemic JJ 1015 1020 cells cell NNS 1020 1021 , , , 1022 1028 TL-Om1 TL-Om1 NNP 1028 1029 , , , 1030 1039 displayed display VBD 1040 1052 constitutive constitutive JJ 1053 1062 NF-kappaB NF-kappaB NNP 1063 1071 activity activity NN 1071 1072 , , , 1073 1075 as as RB 1076 1080 well well RB 1081 1083 as as IN 1084 1092 enhanced enhance VBN 1093 1104 degradation degradation NN 1105 1107 of of IN 1108 1120 IkappaBalpha IkappaBalpha NNP 1120 1121 , , , 1122 1129 despite despite IN 1130 1133 the the DT 1134 1138 lack lack NN 1139 1141 of of IN 1142 1152 detectable detectable JJ 1153 1156 Tax Tax NNP 1157 1167 expression expression NN 1167 1168 . . . 1169 1182 Interestingly interestingly RB 1182 1183 , , , 1184 1187 the the DT 1188 1197 NF-kappaB NF-kappaB NNP 1198 1200 in in IN 1201 1207 TL-Om1 TL-Om1 NNP 1208 1216 consists consist VBZ 1217 1219 of of IN 1220 1227 p50/p50 p50/p50 NN 1228 1231 and and CC 1232 1239 p50/p65 p50/p65 NN 1240 1244 like like IN 1245 1249 that that DT 1250 1252 in in IN 1253 1258 fresh fresh JJ 1259 1266 primary primary JJ 1267 1275 leukemic leukemic JJ 1276 1281 cells cell NNS 1281 1282 . . . 1283 1286 Our our PRP$ 1287 1294 results result NNS 1295 1302 suggest suggest VBP 1303 1307 that that IN 1308 1318 activation activation NN 1319 1321 of of IN 1322 1331 NF-kappaB NF-kappaB NNP 1332 1338 occurs occur VBZ 1339 1346 through through IN 1347 1348 a a DT 1349 1364 Tax-independent tax-independent JJ 1365 1374 mechanism mechanism NN 1375 1377 in in IN 1378 1386 leukemic leukemic JJ 1387 1392 cells cell NNS 1393 1395 of of IN 1396 1399 ATL atl NN 1400 1408 patients patient NNS 1408 1409 , , , 1410 1418 possibly possibly RB 1419 1422 due due JJ 1423 1425 to to TO 1426 1438 differential differential JJ 1439 1448 NF-kappaB NF-kappaB NNP 1449 1456 subunit subunit NN 1457 1467 activation activation NN 1467 1468 . . .